Question · asked by 1 review
Adalimumab vs placebo: Withdrawals due to adverse events
- Population
- Participants with Crohn's disease in remission
- Intervention
- Adalimumab
- Comparison
- placebo
- Outcome
- Withdrawals due to adverse events
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Adalimumab vs placebo Withdrawals due to adverse events · People with quiescent Crohn's disease Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty). Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane Headline outcomes only | RR 0.59 [0.38, 0.91] | 4 studies · 1012 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Adalimumab vs active comparators · People with quiescent Crohn's disease (ileocolic resection) · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.